Chin Eric
Chin Eric's purchase track record
Chin Eric has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/26/2026 | BMRA | $10K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Astrana Health Forms Multi-State Partnership With Verda Healthcare. Astrana Health announced a multi-state partnership with Verda Healthcare to expand culturally tailored care in underserved U.S. communities. This move aims to broaden the company's reach, though some market observers note the stock may already reflect the value of this new agreement. The company also scheduled its Q3 2026 financial results release, keeping investors focused on upcoming performance metrics.
Transaction History
| BMRA | ▲ Buy | Open Market | 6,250 | $10K | 8/26/2026 | View on chart |
| BMRA | ▲ Buy | Grant | 22,500 | $0 | 12/12/2025 | View on chart |
| ASTH | ▼ Sell | Tax Withholding | 469 | $23K | 3/31/2022 | View on chart |
| ASTH | ▼ Sell | Tax Withholding | 2,802 | $142K | 2/3/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Biomerica reports Q1 earnings with lower EPS and sales
Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.
Biomerica reports Q1 earnings with lower EPS and sales. Biomerica released its first‑quarter results, showing earnings per share of $0.37 and revenue of $1.265 million, both lower than the prior year’s $1.38 million sales figure. The decline in sales highlights a contraction in top‑line performance for the quarter. The company’s shares are currently near the lower end of its 52‑week range, which may provide context for market participants.